Details for New Drug Application (NDA): 021191
✉ Email this page to a colleague
The generic ingredient in IMAGENT is perflubron. Additional details are available on the perflubron profile page.
Summary for 021191
| Tradename: | IMAGENT |
| Applicant: | Vesselon Spv Llc |
| Ingredient: | dimyristoyl lecithin; perflexane |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INTRAVENOUS | Strength | 0.92MG/VIAL;0.092MG/VIAL | ||||
| Approval Date: | May 31, 2002 | TE: | RLD: | No | |||||
Expired US Patents for NDA 021191
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Vesselon Spv Llc | IMAGENT | dimyristoyl lecithin; perflexane | INJECTABLE;INTRAVENOUS | 021191-001 | May 31, 2002 | ⤷ Get Started Free | ⤷ Get Started Free |
| Vesselon Spv Llc | IMAGENT | dimyristoyl lecithin; perflexane | INJECTABLE;INTRAVENOUS | 021191-001 | May 31, 2002 | ⤷ Get Started Free | ⤷ Get Started Free |
| Vesselon Spv Llc | IMAGENT | dimyristoyl lecithin; perflexane | INJECTABLE;INTRAVENOUS | 021191-001 | May 31, 2002 | ⤷ Get Started Free | ⤷ Get Started Free |
| Vesselon Spv Llc | IMAGENT | dimyristoyl lecithin; perflexane | INJECTABLE;INTRAVENOUS | 021191-001 | May 31, 2002 | ⤷ Get Started Free | ⤷ Get Started Free |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
